TRCT
SANA icon

Tower Research Capital (TRC)’s Sana Biotechnology SANA Stock Holding History

Tower Research Capital (TRC)’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Buy
44,061
+42,477
+2,682% +$167K ﹤0.01% 1993
2025
Q4 		$6.45K Sell
1,584
-6,575
-81% -$29.4K ﹤0.01% 4064
2025
Q3 		$29K Sell
8,159
-21,488
-72% -$77.7K ﹤0.01% 2969
2025
Q2 		$80.9K Sell
29,647
-8,639
-23% -$17.8K ﹤0.01% 2556
2025
Q1 		$64.3K Buy
38,286
+23,150
+153% +$64.7K ﹤0.01% 2044
2024
Q4 		$24.7K Buy
15,136
+10,548
+230% +$31.5K ﹤0.01% 3037
2024
Q3 		$19.1K Sell
4,588
-14,001
-75% -$73.6K ﹤0.01% 3263
2024
Q2 		$101K Buy
18,589
+17,367
+1,421% +$138K ﹤0.01% 2570
2024
Q1 		$12.2K Sell
1,222
-32,885
-96% -$246K ﹤0.01% 3500
2023
Q4 		$139K Buy
34,107
+30,796
+930% +$113K ﹤0.01% 2375
2023
Q3 		$12.8K Sell
3,311
-8,732
-73% -$46.9K ﹤0.01% 3857
2023
Q2 		$71.8K Buy
12,043
+7,228
+150% +$41.7K ﹤0.01% 2287
2023
Q1 		$16K Buy
4,815
+3,337
+226% +$13.3K ﹤0.01% 3732
2022
Q4 		$5K Sell
1,478
-26,170
-95% -$128K ﹤0.01% 4904
2022
Q3 		$166K Buy
27,648
+13,284
+92% +$95.9K ﹤0.01% 2105
2022
Q2 		$92K Buy
14,364
+6,594
+85% +$42K ﹤0.01% 2362
2022
Q1 		$64K Buy
7,770
+376
+5% +$3.04K ﹤0.01% 2540
2021
Q4 		$115K Buy
7,394
+2,319
+46% +$44.7K ﹤0.01% 2150
2021
Q3 		$114K Buy
5,075
+1,609
+46% +$33.8K ﹤0.01% 2287
2021
Q2 		$68K Buy
3,466
+3,066
+767% +$69.5K ﹤0.01% 2761
2021
Q1 		$13K Buy
+400
New +$13K ﹤0.01% 4220

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Tower Research Capital (TRC)'s SANA Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Sana Biotechnology (SANA) stake by 2,682% in Q1 2026, buying an estimated $167K and bringing the position to 44,061 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1993.

Tower Research Capital (TRC) first reported a position in SANA in Q1 2021 and has held it in 21 quarters since. The position peaked at $166K in Q3 2022. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • Tower Research Capital (TRC) held 44,061 shares of Sana Biotechnology worth $127K as of Q1 2026.
  • Tower Research Capital (TRC) bought 42,477 Sana Biotechnology shares in Q1 2026, an estimated $167K.
  • Sana Biotechnology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1993 holding.
  • Tower Research Capital (TRC) first reported a position in Sana Biotechnology in Q1 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Sana Biotechnology position peaked at $166K in Q3 2022.
  • 202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.